SK Bioscience Vaccine Factory Andong L House▶ Click here for a larger view
SK Bioscience’s KOSPI listing, which succeeded in a record box office success in the public offering stock subscription, is approaching one day ahead.
Investors are paying attention to whether it is possible for SK Bioscience to take over the subscription fever and double the initial price on the first day of listing and soar to the upper limit.
According to the Korea Exchange on the 17th, SK Bioscience will start trading in the securities market with the opening of the stock market on the 18th.
Quotes are accepted from 8:30 am to 9:00 am on the listing date, and the initial price is set in the range of 90 to 200% of the public offering price.
Therefore, the initial price of SK Bioscience, with an offering price of 65,000 won, is determined between 58,500 won and 130,000 won.
If the initial price is set at 130,000 won and goes directly to the upper limit, SK Bioscience can go up to 169,000 won on the listing date.
If this is successful, the market capitalization will increase from 4,9 trillion won based on the public offering price to 12.9 trillion won at once.
SK Biopharmaceuticals and Kakao Games, which recorded a’tasang’ after entering the stock market last year, ended at the upper limit for 3 consecutive trading days and 2 consecutive trading days from the date of listing, respectively.
▶ Click here for a larger view
As SK Bioscience has surpassed SK Biopharmaceutical and Kakao Games in demand forecasting for institutional investors and general subscription, it is observed that it is worth expecting a’tasang’.
In particular, there are few stocks that can be circulated on the listing date, so there is a possibility that the stock price will rise sharply.
According to the securities issuance performance report disclosed by SK Bioscience, 1,762,290 shares, which account for 85.26% of the 12,622,500 shares allocated by the institution, promised to hold mandatory retention for a minimum of 15 days to a maximum of 6 months. did.
In terms of the amount allocated, institutional investors have a higher percentage of obligatory holdings than Big Hit (78.37%), Kakao Games (72.57%), and SK Biopharm (52.25%).
Accordingly, the stocks that are restricted in distribution immediately after listing are 67.62,490 shares, including 52.35 million shares owned by SK Chemicals, the largest shareholder, and 4.44 million shares allocated to employee stock ownership associations, including the amount of institutional obligations to be held.
This is 88.37% of SK Bioscience’s total issued stock of 76.5 million shares. In other words, the number of shares available for circulation on the date of listing is 88,973,510, which is only 11.63% of the issued shares.
The ratio of shares available for distribution on the day of listing is lower than that of SK Biopharm (13.06%), Kakao Games (20.51%), and Big Hit (19.79%).
[연합뉴스]
Copyrights ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited